CYP2J2

Across TCGA pan-cancer cohorts, CYP2J2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CYP2J2 data layer compared with 19 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CYP2J2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CYP2J2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, HNSC, and LSCC are the cancer types where CYP2J2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.967	0.519	.001	50	view →
HNSC	DFS	Tertile	III,IV	0.910	0.502	.009	10	view →
LSCC	DFS	Median	All	1.000	0.275	.010	4	view →
LUAD	DFS	Median	All	0.490	0.809	.025	2	view →
PDAC	DFS	Tertile	All	0.623	0.389	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CYP2J2–CCRCC (DFS)

Open the CCRCC breakdown →